Press "Enter" to skip to content

Cipla acquires brand, trademark rights for anti-diabetic drug Vysov in India

Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.

Original source: https://health.economictimes.indiatimes.com/news/pharma/cipla-acquires-brand-trademark-rights-for-anti-diabetic-drug-vysov-in-india/72758261?utm_source=RSS&utm_medium=ETRSS

Also Read:   Dr Reddy's launches anti-coagulant drug in US market